Phase III randomized trial of thalidomide/dexamethasone vs VAD [vincristine + doxorubicin + dexamethasone] as induction chemotherapy for newly diagnosed myeloma patients and evaluation of the effects of zoledronate [zoledronic acid] on chemotherapy induced apoptosis and antigen presentation.

Trial Profile

Phase III randomized trial of thalidomide/dexamethasone vs VAD [vincristine + doxorubicin + dexamethasone] as induction chemotherapy for newly diagnosed myeloma patients and evaluation of the effects of zoledronate [zoledronic acid] on chemotherapy induced apoptosis and antigen presentation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2014

At a glance

  • Drugs Dexamethasone (Primary) ; Thalidomide (Primary) ; Zoledronic acid (Primary) ; Doxorubicin; Vincristine
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Planned end date changed from 1 May 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top